Activated c-Met signals through PI3K with dramatic effects on cytoskeletal functions in small cell lung cancer

G. Maulik, P. Madhiwala, S. Brooks, P. C. Ma, T. Kijima, E. V. Tibaldi, E. Schaefer, K. Parmar, Ravi Salgia

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

Small cell lung cancer (SCLC) is an aggressive illness with early metastases. There are several receptor tyrosine kinases (RTKs) overexpressed in SCLC, including c-Met. c-Met contains an external semaphorin-like domain, a cytoplasmic juxtamembrane domain, tyrosine kinase domain and multiple tyrosines that bind to adapter molecules. We have previously reported that c-Met is abundantly expressed in the NCI-H69 SCLC cell line and now have determined the downstream effects of stimulating c-Met via its ligand hepatocyte growth factor (HGF). Utilizing unique phospho-specific antibodies generated against various tyrosines of c-Met, we show that Y1003 (binding site for c-Cbl and a negative regulatory site), Y1313 (binding site for PI3K), Y1230/Y1234/Y1235 (autophosphorylation site), Y1349 (binding site for Grb2), Y1365 (important in cell morphogenesis) are phosphorylated in response to HGF (40 ng/ml, 7.5 min) in H69 cells. Since multiple biological and biochemical effects are transduced through the PI3K pathway, we determine the role of PI3K in the c-Met/HGF stimulation pathway. We initially determined that by inhibiting PI3K with LY294002 (50 M over 72 hours), there was at least a 55% decrease in viability of H69 cells. Since H69 SCLC cells form clusters in cell culture, we determined the effects of HGF and LY294002 on cell motility of the clusters by time-lapse video microscopy. In response to HGF, SCLC moved much faster and formed more clusters, and this was inhibited by LY294002. Finally, we determined the downstream signal transduction of HGF stimulation of c-Met with and without inhibition of c-Met (with geldanamycin, an anisamycin antibiotic that inhibits c-Met in SCLC) or PI3K (with LY294002). We show that association of c-Met with PI3K and GAB2 is diminished by inhibiting c-Met. In summary, activation of the c-Met pathway targets the PI3K pathway in SCLC and this may be an important therapeutic target.

Original languageEnglish (US)
Pages (from-to)539-553
Number of pages15
JournalJournal of Cellular and Molecular Medicine
Volume6
Issue number4
DOIs
StatePublished - Jan 1 2002

Fingerprint

Small Cell Lung Carcinoma
Hepatocyte Growth Factor
Phosphatidylinositol 3-Kinases
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one
Binding Sites
Tyrosine
Phospho-Specific Antibodies
Semaphorins
Video Microscopy
Receptor Protein-Tyrosine Kinases
Morphogenesis
Protein-Tyrosine Kinases
Cell Movement
Signal Transduction
Cell Survival
Cell Culture Techniques
Neoplasm Metastasis
Anti-Bacterial Agents
Ligands
Cell Line

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Cell Biology

Cite this

Maulik, G. ; Madhiwala, P. ; Brooks, S. ; Ma, P. C. ; Kijima, T. ; Tibaldi, E. V. ; Schaefer, E. ; Parmar, K. ; Salgia, Ravi. / Activated c-Met signals through PI3K with dramatic effects on cytoskeletal functions in small cell lung cancer. In: Journal of Cellular and Molecular Medicine. 2002 ; Vol. 6, No. 4. pp. 539-553.
@article{73f6b706fd6246958b9d9a6e26b7a7d1,
title = "Activated c-Met signals through PI3K with dramatic effects on cytoskeletal functions in small cell lung cancer",
abstract = "Small cell lung cancer (SCLC) is an aggressive illness with early metastases. There are several receptor tyrosine kinases (RTKs) overexpressed in SCLC, including c-Met. c-Met contains an external semaphorin-like domain, a cytoplasmic juxtamembrane domain, tyrosine kinase domain and multiple tyrosines that bind to adapter molecules. We have previously reported that c-Met is abundantly expressed in the NCI-H69 SCLC cell line and now have determined the downstream effects of stimulating c-Met via its ligand hepatocyte growth factor (HGF). Utilizing unique phospho-specific antibodies generated against various tyrosines of c-Met, we show that Y1003 (binding site for c-Cbl and a negative regulatory site), Y1313 (binding site for PI3K), Y1230/Y1234/Y1235 (autophosphorylation site), Y1349 (binding site for Grb2), Y1365 (important in cell morphogenesis) are phosphorylated in response to HGF (40 ng/ml, 7.5 min) in H69 cells. Since multiple biological and biochemical effects are transduced through the PI3K pathway, we determine the role of PI3K in the c-Met/HGF stimulation pathway. We initially determined that by inhibiting PI3K with LY294002 (50 M over 72 hours), there was at least a 55{\%} decrease in viability of H69 cells. Since H69 SCLC cells form clusters in cell culture, we determined the effects of HGF and LY294002 on cell motility of the clusters by time-lapse video microscopy. In response to HGF, SCLC moved much faster and formed more clusters, and this was inhibited by LY294002. Finally, we determined the downstream signal transduction of HGF stimulation of c-Met with and without inhibition of c-Met (with geldanamycin, an anisamycin antibiotic that inhibits c-Met in SCLC) or PI3K (with LY294002). We show that association of c-Met with PI3K and GAB2 is diminished by inhibiting c-Met. In summary, activation of the c-Met pathway targets the PI3K pathway in SCLC and this may be an important therapeutic target.",
author = "G. Maulik and P. Madhiwala and S. Brooks and Ma, {P. C.} and T. Kijima and Tibaldi, {E. V.} and E. Schaefer and K. Parmar and Ravi Salgia",
year = "2002",
month = "1",
day = "1",
doi = "10.1111/j.1582-4934.2002.tb00453.x",
language = "English (US)",
volume = "6",
pages = "539--553",
journal = "Journal of Cellular and Molecular Medicine",
issn = "1582-1838",
publisher = "Wiley-Blackwell",
number = "4",

}

Activated c-Met signals through PI3K with dramatic effects on cytoskeletal functions in small cell lung cancer. / Maulik, G.; Madhiwala, P.; Brooks, S.; Ma, P. C.; Kijima, T.; Tibaldi, E. V.; Schaefer, E.; Parmar, K.; Salgia, Ravi.

In: Journal of Cellular and Molecular Medicine, Vol. 6, No. 4, 01.01.2002, p. 539-553.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Activated c-Met signals through PI3K with dramatic effects on cytoskeletal functions in small cell lung cancer

AU - Maulik, G.

AU - Madhiwala, P.

AU - Brooks, S.

AU - Ma, P. C.

AU - Kijima, T.

AU - Tibaldi, E. V.

AU - Schaefer, E.

AU - Parmar, K.

AU - Salgia, Ravi

PY - 2002/1/1

Y1 - 2002/1/1

N2 - Small cell lung cancer (SCLC) is an aggressive illness with early metastases. There are several receptor tyrosine kinases (RTKs) overexpressed in SCLC, including c-Met. c-Met contains an external semaphorin-like domain, a cytoplasmic juxtamembrane domain, tyrosine kinase domain and multiple tyrosines that bind to adapter molecules. We have previously reported that c-Met is abundantly expressed in the NCI-H69 SCLC cell line and now have determined the downstream effects of stimulating c-Met via its ligand hepatocyte growth factor (HGF). Utilizing unique phospho-specific antibodies generated against various tyrosines of c-Met, we show that Y1003 (binding site for c-Cbl and a negative regulatory site), Y1313 (binding site for PI3K), Y1230/Y1234/Y1235 (autophosphorylation site), Y1349 (binding site for Grb2), Y1365 (important in cell morphogenesis) are phosphorylated in response to HGF (40 ng/ml, 7.5 min) in H69 cells. Since multiple biological and biochemical effects are transduced through the PI3K pathway, we determine the role of PI3K in the c-Met/HGF stimulation pathway. We initially determined that by inhibiting PI3K with LY294002 (50 M over 72 hours), there was at least a 55% decrease in viability of H69 cells. Since H69 SCLC cells form clusters in cell culture, we determined the effects of HGF and LY294002 on cell motility of the clusters by time-lapse video microscopy. In response to HGF, SCLC moved much faster and formed more clusters, and this was inhibited by LY294002. Finally, we determined the downstream signal transduction of HGF stimulation of c-Met with and without inhibition of c-Met (with geldanamycin, an anisamycin antibiotic that inhibits c-Met in SCLC) or PI3K (with LY294002). We show that association of c-Met with PI3K and GAB2 is diminished by inhibiting c-Met. In summary, activation of the c-Met pathway targets the PI3K pathway in SCLC and this may be an important therapeutic target.

AB - Small cell lung cancer (SCLC) is an aggressive illness with early metastases. There are several receptor tyrosine kinases (RTKs) overexpressed in SCLC, including c-Met. c-Met contains an external semaphorin-like domain, a cytoplasmic juxtamembrane domain, tyrosine kinase domain and multiple tyrosines that bind to adapter molecules. We have previously reported that c-Met is abundantly expressed in the NCI-H69 SCLC cell line and now have determined the downstream effects of stimulating c-Met via its ligand hepatocyte growth factor (HGF). Utilizing unique phospho-specific antibodies generated against various tyrosines of c-Met, we show that Y1003 (binding site for c-Cbl and a negative regulatory site), Y1313 (binding site for PI3K), Y1230/Y1234/Y1235 (autophosphorylation site), Y1349 (binding site for Grb2), Y1365 (important in cell morphogenesis) are phosphorylated in response to HGF (40 ng/ml, 7.5 min) in H69 cells. Since multiple biological and biochemical effects are transduced through the PI3K pathway, we determine the role of PI3K in the c-Met/HGF stimulation pathway. We initially determined that by inhibiting PI3K with LY294002 (50 M over 72 hours), there was at least a 55% decrease in viability of H69 cells. Since H69 SCLC cells form clusters in cell culture, we determined the effects of HGF and LY294002 on cell motility of the clusters by time-lapse video microscopy. In response to HGF, SCLC moved much faster and formed more clusters, and this was inhibited by LY294002. Finally, we determined the downstream signal transduction of HGF stimulation of c-Met with and without inhibition of c-Met (with geldanamycin, an anisamycin antibiotic that inhibits c-Met in SCLC) or PI3K (with LY294002). We show that association of c-Met with PI3K and GAB2 is diminished by inhibiting c-Met. In summary, activation of the c-Met pathway targets the PI3K pathway in SCLC and this may be an important therapeutic target.

UR - http://www.scopus.com/inward/record.url?scp=0037686249&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037686249&partnerID=8YFLogxK

U2 - 10.1111/j.1582-4934.2002.tb00453.x

DO - 10.1111/j.1582-4934.2002.tb00453.x

M3 - Article

C2 - 12611639

AN - SCOPUS:0037686249

VL - 6

SP - 539

EP - 553

JO - Journal of Cellular and Molecular Medicine

JF - Journal of Cellular and Molecular Medicine

SN - 1582-1838

IS - 4

ER -